Contrast-induced kidney injury: Mechanisms, risk factors, and prevention

European Heart Journal

Volumn 33, Issue 16, 2012, Pages 2007-2015

  Seeliger, Erdmann ^a   Sendeski, Mauricio ^a   Rihal, Charanjit S ^b   Persson, Pontus B ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAYO CLINIC   (United States)

Author keywords

Acute kidney injury; Iodinated contrast media; Pathophysiology; Prevention

Indexed keywords

BICARBONATE; CONTRAST MEDIUM; CREATININE; NITRIC OXIDE; SUPEROXIDE; TROPONIN;

BICARBONATE BLOOD LEVEL; BLOOD VISCOSITY; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; GLOMERULUS FILTRATION RATE; HUMAN; HYDRATION; HYPOXIA; IN VITRO STUDY; OSMOLARITY; OXYGENATION; PHOTOLYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SODIUM ABSORPTION; VASOCONSTRICTION;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD VISCOSITY; CELL HYPOXIA; CONTRAST MEDIA; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLOMERULAR FILTRATION RATE; HUMANS; IODINE COMPOUNDS; KIDNEY MEDULLA; OSMOLAR CONCENTRATION; RATS; RISK FACTORS; VASOCONSTRICTION;

EID: 84865212795     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr494     Document Type: Review

References (140)

1. Waybill MM, Waybill PN. Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. J Vasc Interv Radiol 2001;12:3-9.
2. McCullough PA. Radiocontrast-induced acute kidney injury. Nephron Physiol 2008;109:61-72.
3. Solomon R, Dauerman HL. Contrast-induced acute kidney injury. Circulation 2010;122:2451-2455.
4. Gruber L. Clinical features and prognostic implications of contrast-induced nephropathy. In: Bartorelli AL, Marenzi G (eds), Contrast-Induced Nephropathy. London: Taylor & Francis; 2006. p35-45.
5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489-1494.
6. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, Singh M, Bell MR, Barsness GW, Mathew V, Garratt KN, Holmes DR Jr. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-2264.
7. Solomon RJ, Mehran R, Natarajan MK, Doucet S, Katholi RE, Staniloae CS, Sharma SK, Labinaz M, Gelormini JL, Barrett BJ. Contrast-induced nephropathy and long-term adverse events: cause and effect? Clin J Am Soc Nephrol 2009;4: 1162-1169.
8. Reinecke H, Fobker M, Wellmann J, Becke B, Fleiter J, Heitmeyer C, Breithardt G, Hense HW, Schaefer RM. A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol 2007;96:130-139.
9. Sendeski MM. The pathophysiology of renal tissue damage by iodinated contrast media. Clin Exp Pharmacol Physiol 2011;38:292-299.
10. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765-2779.
11. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98: 14K-20K.
12. Calvin AD, Misra S, Pflueger A. Contrast-induced acute kidney injury and diabetic nephropathy. Nat Rev Nephrol 2010;6:679-688.
13. Jost G, Lengsfeld P, Lenhard DC, Pietsch H, Hutter J, Sieber MA. Viscosity of iodinated contrast agents during renal excretion. Eur J Radiol 2011;80:373-377.
14. Jost G, Pietsch H, Sommer J, Sandner P, Lengsfeld P, Seidensticker P, Lehr S, Hutter J, Sieber MA. Retention of iodine and expression of biomarkers for renal damage in the kidney after application of iodinated contrast media in rats. Invest Radiol 2009;44:114-123.
15. Speck U. X-ray contrast media: physico-chemical properties. In: Dawson P, Cosgrove DO, Grainger RG (eds), Textbook of Contrast Media. Oxford: Informa Health Care; 1999. p35-46.
16. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: what do we really know from evidence-based findings? J Nephrol 2009;22: 333-351.
17. Solomon R, Segal A. Defining acute kidney injury: what is the most appropriate metric? Nat Clin Pract Nephrol 2008;4:208-215.
18. Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009;20:672-679.
19. Russo D, Minutolo R, Cianciaruso B, Memoli B, Conte G, De Nicola L. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995;6:1451-1458.
20. Bakris GL, Lass NA, Glock D. Renal hemodynamics in radiocontrast medium-induced renal dysfunction: a role for dopamine-1 receptors. Kidney Int 1999;56:206-210.
21. Seeliger E, Becker K, Ladwig M, Wronski T, Persson PB, Flemming B. Up to 50-fold increase in urine viscosity with iso-osmolar contrast media in the rat. Radiology 2010;256:406-414.
22. Katzberg RW, Newhouse JH. Intravenous contrast medium-induced nephrotox-icity: is the medical risk really as great as we have come to believe? Radiology 2010;256:21-28.
23. Harjai KJ, Raizada A, Shenoy C, Sattur S, Orshaw P, Yaeger K, Boura J, Aboufares A, Sporn D, Stapleton D. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008;101:812-819.
24. Budano C, Levis M, D'Amico M, Usmiani T, Fava A, Sbarra P, Burdese M, Segoloni GP, Colombo A, Marra S. Impact of contrast-induced acute kidney injury definition on clinical outcomes. Am Heart J 2011;161:963-971.
25. Li J, Solomon RJ. Creatinine increases after intravenous contrast administration: incidence and impact. Invest Radiol 2010;45:471-476.
26. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, Almen T, Aspelin P, Bellin MF, Clement O, Heinz-Peer G. Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011;12:2527-2541.
27. Weisbord SD, Palevsky PM. Acute kidney injury: kidney injury after contrast media: marker or mediator? Nat Rev Nephrol 2010;6:634-636.
28. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med 2008; 36(Suppl. 4):S204-S211.
29. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 2008;3:273-280.
30. Fischereder M. Use of intravenous sodium bicarbonate might increase the risk of contrast nephropathy. Nat Clin Pract Nephrol 2008;4:296-297.
31. Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 2007;16:336-347.
32. Heyman SN, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia adaptation, and the pathogenesis of radiocontrast nephropathy. Clin J Am Soc Nephrol 2008;3:288-296.
33. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005;68:14-22.
34. Bartorelli AL, Marenzi G. Contrast-induced nephropathy. J Interv Cardiol 2008;21: 74-85.
35. Kim SJ, Salem MR, Joseph NJ, Madayag MA, Cavallino RP, Crystal GJ. Contrast media adversely affect oxyhemoglobin dissociation. Anesth Analg 1990;71:73-76.
36. Heinrich MC, Kuhlmann MK, Grgic A, Heckmann M, Kramann B, Uder M. Cyto-toxic effects of ionic high-osmolar, nonionic monomeric, and nonionic iso-osmolar dimeric iodinated contrast media on renal tubular cells in vitro. Radiology 2005;235:843-849.
37. Thomsen HS, Morcos SK, Barrett BJ. Contrast-induced nephropathy: the wheel has turned 360 degrees. Acta Radiol 2008;49:646-657.
38. Lineaweaver W, McMorris S, Soucy D, Howard R. Cellular and bacterial toxici-ties of topical antimicrobials. Plast Reconstr Surg 1985;75:394-396.
39. Eloy R, Corot C, Belleville J. Contrast media for angiography: physicochemical properties, pharmacokinetics and biocompatibility. Clin Mater 1991;7:89-197.
40. Fanning NF, Manning BJ, Buckley J, Redmond HP. Iodinated contrast media induce neutrophil apoptosis through a mitochondrial and caspase mediated pathway. Br J Radiol 2002;75:861-873.
41. Hsu YC, Nomura S, Krus CW. Some bactericidal and virucidal properties of iodine not affecting infectious RNA and DNA. Am J Epidemiol 1965;82:317-328.
42. Wasaki M, Sugimoto J, Shirota K. Glucose alters the susceptibility of mesangial cells to contrast media. Invest Radiol 2001;36:355-362.
43. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, Hill JA, Winniford M, Cohen MB, VanFossen DB. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995;47:254-261.
44. Pallone TL, Zhang Z, Rhinehart K. Physiology of the renal medullary microcirculation. Am J Physiol Renal Physiol 2003;284:F253-F266.
45. Sendeski M, Patzak A, Pallone TL, Cao C, Persson AE, Persson PB. Iodixanol, constriction of medullary descending vasa recta, and risk for contrast medium-induced nephropathy. Radiology 2009;251:697-704.
46. Cao C, Edwards Al, Sendeski M, Lee-Kwon W, Cui L, Cai CY, Patzak A, Pallone TL. Intrinsic nitric oxide and superoxide production regulates descending vasa recta contraction. Am J Physiol Renal Physiol 2010;299:F1056-F1064.
47. Sendeski M, Patzak A, Persson PB. Constriction of the vasa recta, the vessels supplying the area at risk for acute kidney injury, by four different iodinated contrast media, evaluating ionic, nonionic, monomeric and dimeric agents. Invest Radiol 2010;45:453-457.
48. Gospos C, Koch HK, Mathias K, Seemann W, Tan KG, Papacharalampous X. Scanning electron microscopic (SEM) studies on the effect of x-ray contrast media on aortic endothelium in the rat. Invest Radiol 1983;18:382-386.
49. Aliev G, Obrenovich ME, Seyidova D, Rzayev NM, Aliyev AS, Raina AK, Lamanna JC, Smith MA, Perry G. X-ray contrast media induce aortic endothelial damage, which can be prevented with prior heparin treatment. J Submicrosc Cytol Pathol 2003;35:253-266.
50. Heyman SN, Clark BA, Cantley L, Spokes K, Rosen S, Brezis M, Epstein FH. Effects of ioversol versus iothalamate on endothelin release and radiocontrast nephropathy. Invest Radiol 1993;28:313-318.
51. Messana JM, Cieslinski DA, Humes HD. Comparison of toxicity of radiocontrast agents to renal tubule cells in vitro. Ren Fail 1990;12:75-82.
52. Galtung HK, Loeken M, Sakariassen KS. Effect of radiologic contrast media on cell volume regulation in rabbit proximal renal tubules. Acad Radiol 2001;8: 398-404.
53. Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol 2002;37:428-434.
54. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. Am J Kidney Dis 2008;51:491-503.
55. Heinrich MC. Osmotic nephrosis and contrast media. Am J Kidney Dis 2008;52: 629-630.
56. Liss P, Nygren A, Ulfendahl HR, Erikson U. Effect of furosemide or mannitol before injection of a non-ionic contrast medium on intrarenal oxygen tension. Adv Exp Med Biol 1999;471:353-359.
57. Morcos SK, Dawson P, Pearson JD, Jeremy JY, Davenport AP, Yates MS, Tirone P, Cipolla P, de Haen C, Muschick P, Krause W, Refsum H, Emery CJ, Liss P, Nygren A, Haylor J, Pugh ND, Karlsson JO. The haemodynamic effects of iodinated water soluble radiographic contrast media: a review. Eur J Radiol 1998;29:31-46.
58. Ueda J, Nygren A, Hansell P, Erikson U. Influence of contrast media on single nephron glomerular filtration rate in rat kidney. A comparison between diatrizo-ate, iohexol, ioxaglate, and iotrolan. Acta Radiol 1992;33:596-599.
59. Ueda J, Nygren A, Hansell P, Ulfendahl HR. Effect of intravenous contrast media on proximal and distal tubular hydrostatic pressure in the rat kidney. Acta Radiol 1993;34:83-87.
60. Ueda J, Furukawa T, Higashino K, Takahashi S, Araki Y, Kubo K, Nakashima T. Urine viscosity after injections of iotrolan or iomeprol. Acta Radiol 1997;38: 1079-1082.
61. Lancelot E, Idee JM, Couturier V, Vazin V, Corot C. Influence of the viscosity of iodixanol on medullary and cortical blood flow in the rat kidney: a potential cause of nephrotoxicity. J Appl Toxicol 1999;19:341-346.
62. Lancelot E, Idee JM, Lacledere C, Santus R, Corot C. Effects of two dimeric iodi-nated contrast media on renal medullary blood perfusion and oxygenation in dogs. Invest Radiol 2002;37:368-375.
63. Seeliger E, Flemming B, Wronski T, Ladwig M, Arakelyan K, Godes M, Mockel M, Persson PB. Viscosity of contrast media perturbs renal hemodynamics. J Am Soc Nephrol 2007;18:2912-2920.
64. Ueda J, Nygren A, Sjoquist M, Jacobsson E, Ulfendahl HR, Araki Y. Iodine concentrations in the rat kidney measured by X-ray microanalysis. Comparison of concentrations and viscosities in the proximal tubules and renal pelvis after intravenous injections of contrast media. Acta Radiol 1998;39:90-95.
65. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Sonel AF, Fine MJ, Palevsky PM. Prevention, incidence, and outcomes of contrast-induced acute kidney injury. Arch Intern Med 2008;168:1325-1332.
66. Jost G, Lenhard DC, Sieber MA, Lengsfeld P, Hutter J, Pietsch H. Changes of renal water diffusion coefficient after application of iodinated contrast agents: effect of viscosity. Invest Radiol 2011;46:576-585.
67. Ladwig M, Flemming B, Seeliger E, Sargsyan L, Persson PB. Renal Effects of bicarbonate versus saline infusion for iso-and lowosmolar contrast media in rats. Invest Radiol 2011;46:672-677.
68. Jost G, Pietsch H, Lengsfeld P, Hutter J, Sieber MA. The impact of the viscosity and osmolality of iodine contrast agents on renal elimination. Invest Radiol 2010; 45:255-261.
69. Khraibi AA, Knox FG. Effect of renal decapsulation on renal interstitial hydrostatic pressure and natriuresis. Am J Physiol 1989;257(1 Pt 2):R44-R48.
70. Andersen PE, Bolstad B, Berg KJ, Justesen P, Thayssen P, Kloster YF. Iodixanol and ioxaglate in cardioangiography: a double-blind randomized phase III study. Clin Radiol 1993;48:268-272.
71. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephro-toxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348:491-499.
72. Barrett BJ, Katzberg RW, Thomsen HS, Chen N, Sahani D, Soulez G, Heiken JP, Lepanto L, Ni ZH, Nelson R. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol 2006;41:815-821.
73. Bertrand ME, Esplugas E, Piessens J, Rasch W. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty: a multicenter, randomized, double-blind study. Visipaque in Percutaneous Transluminal Coronary Angio-plasty [VIP] Trial Investigators. Circulation 2000;101:131-136.
74. Carraro M, Malalan F, Antonione R, Stacul F, Cova M, Petz S, Assante M, Grynne B, Haider T, Palma LD, Faccini L. Effects of a dimeric vs. a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a double-blind, randomized clinical trial. Eur Radiol 1998;8: 144-147.
75. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol 1999;72:701-703.
76. Chuang FR, Chen TC, Wang IK, Chuang CH, Chang HW, Ting-Yu CT, Cheng YF, Lee WC, Chen WC, Yang KD, Lee CH. Comparison of iodixanol and iohexol in patients undergoing intravenous pyelography: a prospective controlled study. Ren Fail 2009;31:181-188.
77. Davidson CJ, Laskey WK, Hermiller JB, Harrison JK, Matthai W Jr, Vlietstra RE, Brinker JA, Kereiakes DJ, Muhlestein JB, Lansky A, Popma JJ, Buchbinder M, Hirshfeld JW Jr. Randomized trial of contrast media utilization in high-risk PTCA: the COURT trial. Circulation 2000;101:2172-2177.
78. Feldkamp T, Baumgart D, Elsner M, Herget-Rosenthal S, Pietruck F, Erbel R, Philipp T, Kribben A. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol 2006;66:322-330.
79. Fischbach R, Landwehr P, Lackner K, Nossen JO, Heindel W, Berg KJ, Eichhorn G, Jacobsen TF. Iodixanol vs. iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Eur Radiol 1996;6:9-13.
80. Grossman RI, Modic MT. A randomized comparison of iodixanol and iohexol in adult intracranial computed tomography scanning. Acad Radiol 1996;3(Suppl. 3): S488-S494.
81. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complicat 2008;22:171-177.
82. Hill JA, Cohen MB, Kou WH, Mancini GB, Mansour M, Fountaine H, Brinker JA. Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. Am J Cardiol 1994;74:57-63.
83. Jakobsen JA. Renal effects of iodixanol in healthy volunteers and patients with severe renal failure. Acta Radiol Suppl 1995;399:191-195.
84. Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 2006;48: 924-930.
85. Jorgensen NP, Nossen JO, Borch KW, Kristiansen AB, Kristoffersen DT, Lundby B, Theodorsen L. Safety and tolerability of iodixanol in healthy volunteers with reference to two monomeric X-ray contrast media. Eur J Radiol 1992;15:252-257.
86. Juergens CP, Winter JP, Nguyen-Do P, Lo S, French JK, Hallani H, Fernandes C, Jepson N, Leung DY. Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. Intern Med J 2009; 39:25-31.
87. Klow NE, Levorstad K, Berg KJ, Brodahl U, Endresen K, Kristoffersen DT, Laake B, Simonsen S, Tofte AJ, Lundby B. Iodixanol in cardioangiography in patients with coronary artery disease. Tolerability, cardiac and renal effects. Acta Radiol 1993;34:72-77.
88. Kuhn MJ, Chen N, Sahani DV, Reimer D, van Beek EJ, Heiken JP, So GJ. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low-or isoosmolar contrast agent exposure. AJR Am J Roent-genol 2008;191:151-157.
89. Laskey W, Aspelin P, Davidson C, Rudnick M, Aubry P, Kumar S, Gietzen F, Wiemer M. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 2009;158:822-828.
90. Lee FT Jr, Caroline DF, Thornbury JR, Gembala RB, Kelcz F, Pozniak MA, Rima JB, Sargent BE. A randomized comparison of iodixanol and iohexol in adult body computed tomography scanning. Acad Radiol 1996;3(Suppl. 3): S500-S506.
91. Mehran R, Nikolsky E, Kirtane AJ, Caixeta A, Wong SC, Teirstein PS, Downey WE, Batchelor WB, Casterella PJ, Kim YH, Fahy M, Dangas GD. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. JACC Cardiovasc Interv 2009; 2:415-421.
92. Nguyen SA, Suranyi P, Ravenel JG, Randall PK, Romano PB, Strom KA, Costello P, Schoepf UJ. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology 2008;248:97-105.
93. Nie B, Cheng WJ, Li YF, Cao Z, Yang Q, Zhao YX, Guo YH, Zhou YJ. A prospective, double-blind, randomized, controlled trial on the efficacy and cardior-enal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv 2008;72:958-965.
94. Poirier VC, Newberry PD, Hecht ST, Nemzek WR. Phase III clinical trial comparing iodixanol and iohexol in cerebral angiography. Acad Radiol 1996; 3(Suppl. 3):S495-S499.
95. Pugh ND, Sissons GR, Ruttley MS, Berg KJ, Nossen JO, Eide H. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol 1993;47:96-99.
96. Rosenblum JD, Siegel EL, Leef J, Eckard DA, Lu CT. Iodixanol and ioxaglate in adult aortography and peripheral arteriography: a phase III clinical trial. Acad Radiol 1996;3(Suppl. 3):S514-S518.
97. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008;156:776-782.
98. Schmid I, Didier D, Pfammatter T, Garachemani A, Fleisch M, Kirchin MA, Meier B. Effects of non-ionic iodinated contrast media on patient heart rate and pressures during intra-cardiac or intra-arterial injection. Int J Cardiol 2007; 118:389-396.
99. Siegel EL, Rosenblum JD, Eckard DA, Leef J, Bergh J, Parsa MB, Redick ML. Comparison of iodixanol and ioxaglate for adult aortography and renal/visceral angi-ography: a phase III clinical trial. Acad Radiol 1996;3(Suppl. 3):S507-S513.
100. Singh K, Sundgren R, Bolstad B, Bjork L, Lie M. Iodixanol in abdominal digital subtraction angiography. A randomized, double-blind, parallel trial with iodixanol and iohexol. Acta Radiol 1993;34:242-245.
101. Solomon RJ, Natarajan MK, Doucet S, Sharma SK, Staniloae CS, Katholi RE, Gelormini JL, Labinaz M, Moreyra AE. Cardiac Angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007;115: 3189-3196.
102. Thomsen HS, Morcos SK, Erley CM, Grazioli L, Bonomo L, Ni Z, Romano L. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol 2008;43:170-178.
103. Tveit K, Bolz KD, Bolstad B, Haugland T, Berg KJ, Skjaerpe T, Kloster YF. Iodixanol in cardioangiography. A double-blind parallel comparison between iodixanol 320 mg I/mL and ioxaglate 320 mg I/mL. Acta Radiol 1994;35: 614-618.
104. Verow P, Nossen JO, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography. Br J Radiol 1995;68:973-978.
105. Wessely R, Koppara T, Bradaric C, Vorpahl M, Braun S, Schulz S, Mehilli J, Schomig A, Kastrati A. Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2009;2:430-437.
106. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with low-osmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 2009;2: 645-654.
107. Heinrich MC, Haberle L, Muller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009;250:68-86.
108. From AM, Al Badarin FJ, McDonald FS, Bartholmai BJ, Cha SS, Rihal CS. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephro-pathy: meta-analysis of randomized, controlled trials. Circ Cardiovasc Interv 2010; 3:351-358.
109. Liss P, Persson PB, Hansell P, Lagerqvist B. Renal failure in 57 925 patients undergoing coronary procedures using iso-osmolar or low-osmolar contrast media. Kidney Int 2006;70:1811-1817.
110. Reed MC, Moscucci M, Smith DE, Share D, LaLonde T, Mahmood SA, D'Haem C, McNamara R, Greenbaum A, Gurm HS. The relative renal safety of iodixanol and low-osmolar contrast media in patients undergoing percutaneous coronary intervention. Insights from Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). J Invasive Cardiol 2010;22:467-472.
111. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-375.
112. Cochran ST, Wong WS, Roe DJ. Predicting angiography-induced acute renal function impairment: clinical risk model. AJR Am J Roentgenol 1983;141: 1027-1033.
113. Clark JJ, Wong LL, Lurie F, Kamitaki BK. Proteinuria as a predictor of renal dysfunction in trauma patients receiving intravenous contrast. Am Surg 2011;77: 1194-1200.
114. Thomsen HS, Morcos SK. In which patients should serum creatinine be measured before iodinated contrast medium administration? Eur Radiol, 2005;15:749-754.
115. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, Mintz GS, Lansky AJ, Moses JW, Stone GW, Leon MB, Dangas G. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44: 1393-1399.
116. Kane GC, Doyle BJ, Lerman A, Barsness GW, Best PJ, Rihal CS. Ultra-low contrast volumes reduce rates of contrast-induced nephropathy in patients with chronic kidney disease undergoing coronary angiography. J Am Coll Cardiol 2008;51:89-90.
117. Marenzi G, Assanelli E, Campodonico J, Lauri G, Marana I, De Metrio M, Moltrasio M, Grazi M, Rubino M, Veglia F, Fabbiocchi F, Bartorelli AL. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009;150: 170-177.
118. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-294.
119. Venkataraman R. Can we prevent acute kidney injury? Crit Care Med 2008; 36(Suppl. 4):S166-S171.
120. Briguori C, Marenzi G. Contrast-induced nephropathy: pharmacological prophylaxis. Kidney Int Suppl 2006;(Suppl. 100):S30-S38.
121. Weisbord SD, Palevsky PM. Strategies for the prevention of contrast-induced acute kidney injury. Curr Opin Nephrol Hypertens 2010;19:539-549.
122. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De MM, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354: 2773-2782.
123. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009;122:874-915.
124. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009;4:1584-1592.
125. Berl T, Robertson GL. Pathophysiology of water metabolism. In: Brenner BM (ed.), The Kidney. Philadelphia: Saunders; 2000. p866-924.
126. Reinhardt HW, Seeliger E. Toward an integrative concept of control of total body sodium. News Physiol Sci 2000;15:319-325.
127. Seeliger E, Lunenburg T, Ladwig M, Reinhardt HW. Role of the renin-angiotensin-aldosterone system for control of arterial blood pressure following moderate deficit in total body sodium: balance studies in freely moving dogs. Clin Exp Pharmacol Physiol 2010;37:e43-e51.
128. Seeliger E, Wronski T, Ladwig M, Dobrowolski L, Vogel T, Godes M, Persson PB, Flemming B. The renin-angiotensin system and the third mechanism of renal blood flow autoregulation. Am J Physiol Renal Physiol 2009;296:F1334-F1345.
129. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr 2008;120:742-748.
130. Navaneethan SD, Singh S, Appasamy S, Wing RE, Sehgal AR. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 2009;53:617-627.
131. Hogan SE, L'Allier P, Chetcuti S, Grossman PM, Nallamothu BK, Duvernoy C, Bates E, Moscucci M, Gurm HS. Current role of sodium bicarbonate-based pre-procedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 2008;156:414-421.
132. Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol 2009;41:617-627.
133. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 2009;7:23.
134. Heyman SN, Rosen S, Khamaisi M, Idee JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol 2010;45:188-195.
135. Dubose TD Jr. Reclamation of filtered bicarbonate. Kidney Int 1990;38:584-589.
136. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-1420.
137. Stevens MA, McCullough PA, Tobin KJ, Speck JP, Westveer DC, Guido-Allen DA, Timmis GC, O'Neill WW. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-411.
138. Seeliger E, Ladwig M, Sargsyan L, Cantow K, Persson PB, Flemming B. Proof of principle: hydration by a mannitol-glucose solution alleviates undesirable renal effects of an iso-osmolar contrast medium in rats. Invest Radiol 2012 (in press).
139. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, Golia B, Ricciardelli B, Condorelli G. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury. Circulation 2011;124:1260-1269.
140. Marenzi G, Ferrari C, Marana I, Assanelli E, DeMetrio M, Teruzzi G, Veglia F, Fabbiocchi F, Montorsi P, Bartorelli AL. Prevention of Contrast Nephropathy with Furosemide-Induced Diuresis and Matched Hydration-The MYTHOS trial. JACC Cardiovas Interven 2011 (in press).